MedTrace Logo

Study in Subjects With Small Primary Choroidal Melanoma

NCT03052127 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-02-01

Study results available
· View outcomes & findings →

Summary

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

Conditions

Interventions

DRUG

Light-activated AU-011

Study treatment

DEVICE

Laser Activation

Study treatment

Sponsors & Collaborators

  • Aura Biosciences

    lead INDUSTRY

Principal Investigators

  • Abhijit Narvekar, MBBS · Aura Biosciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-27
Primary Completion
2021-01-26
Completion
2021-01-26
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03052127 on ClinicalTrials.gov